Tyrosine kinase inhibitors (TKIs) used in the management of chronic myeloid leukaemia are associated with haematologic toxicities—Which TKI is the safest?

Eitemau Tebyg

• Chronic myeloid leukaemia and the use of tyrosine kinase inhibitors in the days of COVID‐19 pandemic
  gan: Eşkazan, Ahmet Emre
  Cyhoeddwyd: (2020)
• Tyrosine Kinase Inhibitor Sequencing in Patients with Chronic Myeloid Leukemia
  gan: Mario Tiribelli, et al.
  Cyhoeddwyd: (2019-08-01)
• Tyrosine Kinase Inhibitor Sequencing in Patients with Chronic Myeloid Leukemia
  gan: Tiribelli, Mario, et al.
  Cyhoeddwyd: (2019)
• New drugs approved for acute myeloid leukaemia in 2018
  gan: Kucukyurt, Selin, et al.
  Cyhoeddwyd: (2019)
• Haematological adverse events associated with tyrosine kinase inhibitors in chronic myeloid leukaemia: A network meta‐analysis
  gan: Fachi, Mariana M., et al.
  Cyhoeddwyd: (2019)